Abstract: This disclosure provides methods of treating cancer comprising administering effector cell engaging molecules comprising one or more tumor targeting moieties and one or more effector cell engaging moieties. For example, the effector cell engaging molecules can have a greater cumulative potency for the tumor targeting moieties than the effector cell engaging moieties, the tumor targeting moieties can have greater avidity than the effector cell engaging moieties, and/or can be multimeric. The methods comprise, for example, administering different doses of effector cell engaging molecules based on the subject's symptoms and/or administering chimeric antigen receptor expressing cells.